Affimed N.V. (AFMD)

$0.18 -0.10 (-34.95%)
Market Cap 2.92M
Revenue (ttm) 8.96M
Net Income (ttm) -114.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,279.69%
Debt to Equity Ratio 0.47
Volume 23,468,002
Avg Vol 19,511,936
Day's Range N/A - N/A
Shares Out 16.10M
Stochastic %K 15%
Beta 2.07
Analysts Sell
Price Target $6.83

Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, wh...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 621 560030
Fax: 49 621 56003 649
Address:
Gottlieb-Daimler-Straße 2, Mannheim, Germany
Supplement
Supplement Sep. 12 at 9:07 PM
$AFMD What's the latest news with $AFMD?
1 · Reply
Hodl707
Hodl707 Sep. 12 at 6:39 PM
$AFMD Wahl’s a machine – 47 insolvencies, zero fumbles. Debt 15.6M, IPs worth 420M. He drags to max value, locks Roche, vote’s a stamp. No auction = clean sale. Guy’s greedy, not stupid. That’s why he’s selling fast.
1 · Reply
deathknight
deathknight Sep. 12 at 2:13 AM
$AFMD I believe the company has been in the "for sale" mode since Jan 2024 when they let Adi go and cut the whole R&D department. Adi was the one landed Genentech and Roviant deals and without R&D department the company has no capacity to forge new collaboration/generate more revenues to fund its operation. So M&A has been the only viable path since then. I also believe they dared to do so because they have a clear buyer in mind even some non-binding terms. But the negotiation drags too long and they ended up in current state. It's possible the insolvency is not an administrative blunder but (rather desperate) strategic move. If my hypothesis holds, just keep talking to Roche will only greatly reduce their leverage and an administrator managed public auction can definitely change the pace and each party's stance. Genentech's quick move to terminate collaboration with Bicycle Therapeutics and Adaptive recently might not be a mere coincidence...
1 · Reply
Hodl707
Hodl707 Sep. 11 at 9:55 PM
$AFMD has biotech ever seen insolvency come forth with a 40% AML remission? Am I Trippin or those numbers unprecedented?
1 · Reply
Think_Bigly
Think_Bigly Sep. 9 at 11:50 PM
$AFMD This is clean as any IPO with a platform as developed as theirs.. in the hot spot of immuno-oncology and great PII data. Would easily hit $300M+. Then compare to the Roche $4.9B partner deal.. sounds too low. https://www.affimed.com/pipeline/
0 · Reply
Think_Bigly
Think_Bigly Sep. 9 at 8:40 PM
$AFMD versus IP and PII trials with pristine data. Billions in potential value vs $13.7M LFG Gilde! Defend your investment.
2 · Reply
DrPump_
DrPump_ Sep. 9 at 4:25 PM
$AFMD Per this list: - Total Claims €15,600,000 - Secured: €4,300,000 - Unsecured: €11,300,000 - Key Creditors: 1. Affimed N.V. (Netherlands): €3,500,000 (loan, 100% secured) 2. Thermo Fisher Scientific GmbH: €800,000 (equipment, 70% residual value secured) 3. Heidelberger Renten GmbH: €2,900,000 (rent, unsecured) 4. Employees (25 persons): €4,200,000 (wage arrears May–Aug, unsecured) 5. Roche Deutschland GmbH: €1,100,000 (services/trials, unsecured) 6. Other Suppliers (12): €3,100,000 (open invoices, unsecured)
4 · Reply
Hodl707
Hodl707 Sep. 9 at 1:47 PM
$AFMD neu.insolvenzbekanntmachungen.de → Suche → Affimed GmbH → Aktenzeichen 2 IN 1612/25 → scroll to Bekanntmachungen → PDF dated today, 9.9.2025. It's plain German, but the numbers jump out: - 13.7 Mio € Gesamtansprüche (total claims) - 4.2 Mio € Löhne (salaries) - 3.1 Mio € Lieferanten (vendors) - 2.9 Mio € Miete & Nebenkosten (rent/utilities) - 3.5 Mio € sonstiges (other – looks like a short-term loan from N.V. itself)
3 · Reply
Hodl707
Hodl707 Sep. 9 at 1:44 PM
$AFMD debt 13.7 million low debt
0 · Reply
Hodl707
Hodl707 Sep. 8 at 2:09 PM
$AFMD claims for creditors deadline is approaching. We should know the damages soon, correct?
1 · Reply
Latest News on AFMD
No data available.
Supplement
Supplement Sep. 12 at 9:07 PM
$AFMD What's the latest news with $AFMD?
1 · Reply
Hodl707
Hodl707 Sep. 12 at 6:39 PM
$AFMD Wahl’s a machine – 47 insolvencies, zero fumbles. Debt 15.6M, IPs worth 420M. He drags to max value, locks Roche, vote’s a stamp. No auction = clean sale. Guy’s greedy, not stupid. That’s why he’s selling fast.
1 · Reply
deathknight
deathknight Sep. 12 at 2:13 AM
$AFMD I believe the company has been in the "for sale" mode since Jan 2024 when they let Adi go and cut the whole R&D department. Adi was the one landed Genentech and Roviant deals and without R&D department the company has no capacity to forge new collaboration/generate more revenues to fund its operation. So M&A has been the only viable path since then. I also believe they dared to do so because they have a clear buyer in mind even some non-binding terms. But the negotiation drags too long and they ended up in current state. It's possible the insolvency is not an administrative blunder but (rather desperate) strategic move. If my hypothesis holds, just keep talking to Roche will only greatly reduce their leverage and an administrator managed public auction can definitely change the pace and each party's stance. Genentech's quick move to terminate collaboration with Bicycle Therapeutics and Adaptive recently might not be a mere coincidence...
1 · Reply
Hodl707
Hodl707 Sep. 11 at 9:55 PM
$AFMD has biotech ever seen insolvency come forth with a 40% AML remission? Am I Trippin or those numbers unprecedented?
1 · Reply
Think_Bigly
Think_Bigly Sep. 9 at 11:50 PM
$AFMD This is clean as any IPO with a platform as developed as theirs.. in the hot spot of immuno-oncology and great PII data. Would easily hit $300M+. Then compare to the Roche $4.9B partner deal.. sounds too low. https://www.affimed.com/pipeline/
0 · Reply
Think_Bigly
Think_Bigly Sep. 9 at 8:40 PM
$AFMD versus IP and PII trials with pristine data. Billions in potential value vs $13.7M LFG Gilde! Defend your investment.
2 · Reply
DrPump_
DrPump_ Sep. 9 at 4:25 PM
$AFMD Per this list: - Total Claims €15,600,000 - Secured: €4,300,000 - Unsecured: €11,300,000 - Key Creditors: 1. Affimed N.V. (Netherlands): €3,500,000 (loan, 100% secured) 2. Thermo Fisher Scientific GmbH: €800,000 (equipment, 70% residual value secured) 3. Heidelberger Renten GmbH: €2,900,000 (rent, unsecured) 4. Employees (25 persons): €4,200,000 (wage arrears May–Aug, unsecured) 5. Roche Deutschland GmbH: €1,100,000 (services/trials, unsecured) 6. Other Suppliers (12): €3,100,000 (open invoices, unsecured)
4 · Reply
Hodl707
Hodl707 Sep. 9 at 1:47 PM
$AFMD neu.insolvenzbekanntmachungen.de → Suche → Affimed GmbH → Aktenzeichen 2 IN 1612/25 → scroll to Bekanntmachungen → PDF dated today, 9.9.2025. It's plain German, but the numbers jump out: - 13.7 Mio € Gesamtansprüche (total claims) - 4.2 Mio € Löhne (salaries) - 3.1 Mio € Lieferanten (vendors) - 2.9 Mio € Miete & Nebenkosten (rent/utilities) - 3.5 Mio € sonstiges (other – looks like a short-term loan from N.V. itself)
3 · Reply
Hodl707
Hodl707 Sep. 9 at 1:44 PM
$AFMD debt 13.7 million low debt
0 · Reply
Hodl707
Hodl707 Sep. 8 at 2:09 PM
$AFMD claims for creditors deadline is approaching. We should know the damages soon, correct?
1 · Reply
Hodl707
Hodl707 Sep. 4 at 6:56 PM
$AFMD People get confused because Affimed GmbH (the German lab) holds the day-to-day patents-US 11,098,123 for AFM24, for example-but those titles are legally consolidated under Affimed N.V. (the Dutch parent) in every SEC filing (20-F, 6-K). The big deals with Genentech and Roche are signed by N.V., not GmbH.
1 · Reply
Hodl707
Hodl707 Sep. 3 at 11:28 PM
$AFMD That line-no sufficient assets to cover creditors-means the stuff Affimed GmbH actually owns right now-lab benches, office desks, leftover trial supplies, a couple of bank accounts with peanuts in them-is worth maybe five to ten million euros, tops. It doesn’t include the real gems: the patents for AFM24, AFM28, and the ROCK platform. Those IPs live on Affimed N.V.‘s books
2 · Reply
Think_Bigly
Think_Bigly Sep. 2 at 2:54 AM
$AFMD -Gilde has $2.6B under management. In 3-4 years that could be $6B-$7B in Affimed.. which represents a fantastic growth opportunity for them.. given the trial progress and the great data.
0 · Reply
deathknight
deathknight Sep. 1 at 2:22 PM
$AFMD If this is an asset sale and yes I agree we can only hope to see any recovery after a reasonable IP sale. Unfortunately though, we will need to wait many months even years after the sale to receive (if any) money distributed to shareholders... We are holding shares of parent aka Affimed N.V. so we got paid the last in the parent company's proceeding, after all its creditors got paid in full. The procedure is painfully slow and for the best interest of everyone (buyers included), I really hope folks like Roche/Genentech just buy this out through share transaction -- they can avoid a bid war and keep all clinical regulatory status which can save them years.
1 · Reply
DrPump_
DrPump_ Sep. 1 at 12:24 PM
$AFMD Affimed current shareholders can win just IF patents etc are sold at a fair value. If administrator will sell the IPs for peanuts or “IPs sales price = procedural costs + debts” … so net zero … there will be no enough money left to pay shareholders. Affimed patents have value. IPs value is not subject to fixed assumptions … its the meeting of supply and demand — so everything could happen. Shareholders must remain vigilant. Administrator seems a good guy with nice expertise on the matter. Since shareholders have the right to know whats going on, they can politely send him a mail to understand what’s his plan to maximize Affimed patents value.
0 · Reply
Think_Bigly
Think_Bigly Sep. 1 at 3:17 AM
$AFMD Roche reduces milestones by 80% -Affimed is then eligible for $250 million in developmental milestones, $1.1 billion in regulatory milestones, and $3.5 billion in commercial milestones... and also includes tiered royalties.-All future royalties go to $0.. And the most powerful immuno-oncology platform on earth is theirs: $600M
0 · Reply
Omarhabibeh
Omarhabibeh Aug. 31 at 10:11 AM
$AFMD I am no expert on the market, but could someone please explain what would happen if the short sellers didn’t close their positions? They sold far more than is available.
2 · Reply
Think_Bigly
Think_Bigly Aug. 31 at 6:40 AM
$AFMD some one here has Mad Cow Disease?
0 · Reply
Think_Bigly
Think_Bigly Aug. 30 at 3:52 AM
$AFMD Gilde Healthcare followed Affimed’s development for many years prior to investment. By anchoring an upsized public offering of $103.5m in April 2022, **Gilde enabled crucial financing in a turbulent market environment.** https://gildehealthcare.com/portfolio/venture-and-growth/affimed/
2 · Reply
Think_Bigly
Think_Bigly Aug. 28 at 8:42 PM
$AFMD GILDE fund loses $102M ?? Their best recourse is to offer on the whole company. They have no wherewithal to manage trials or undeveloped IP. Their best move is to pay up.. and keep the company intact so that Roche is running trials per agreement. GILDE could then benefit immensely from future cash flow.
0 · Reply
DrPump_
DrPump_ Aug. 27 at 2:24 PM
$AFMD The assets sales will be through the auctions: its up to the administrator. Acquirer should buy the IPs not the company.
1 · Reply
deathknight
deathknight Aug. 25 at 2:02 AM
$AFMD eventually, it's all about their science and hard data: is it differentiated (it is); has it achieved proof of concept (it has) and is it safe (it is). It checked all my boxes and that's only reason I have invested in them and held faith in the company's value. There's no miracle here -- if the science is good, it will be recognized and acquired for a fair value; if not, it will disappear like all those failed biotechs.
1 · Reply